Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

MRF announces achievement of myelin repair Phase 1 trial for MS

The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.

15 Jun 2012

Minimally invasive procedure to treat high blood pressure

A radically different approach to treating high blood pressure – using a minimally invasive procedure – is being evaluated as part of a Pivotal Phase III 90-site national trial that includes The Carl H. and Edyth Lindner Center for Research and Education at The Christ Hospital.

14 Jun 2012

Embryonic stem cells hold great promise for biomedical science

With their potential to treat a wide range of diseases and uncover fundamental processes that lead to those diseases, embryonic stem (ES) cells hold great promise for biomedical science.

14 Jun 2012

Georgia Tech startup to create new delivery method for cell-based therapies

Cell-based therapies have yet to reach their full potential in repairing damaged tissue because of the hostile environment the cells face once injected into the body. A patient's inflammatory response normally causes the majority of these therapeutic cells to die or migrate away from the area in need of repair.

14 Jun 2012

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up.

14 Jun 2012

Ten young researchers named Pew Latin American Fellows in the Biomedical Sciences

Ten young researchers were named Pew Latin American Fellows in the Biomedical Sciences today by The Pew Charitable Trusts. For these scientists, who have dedicated their careers to finding solutions for some of the world's most troubling health problems, this fellowship will provide support that will further their research, enable them to work with colleagues in the United States, and increase scientific knowledge throughout their home region.

14 Jun 2012

Study investigates how breast cancer cells migrate to bone

Breast cancer cells frequently move from their primary site and invade bone, decreasing a patient's chance of survival. This process of metastasis is complex, and factors both within the breast cancer cells and within the new bone environment play a role. In next week's Journal of Biological Chemistry "Paper of the Week," Roger Gomis and colleagues at the Institute for Research in Biomedicine in Spain investigated how breast cancer cells migrate to bone.

14 Jun 2012

Human-derived stem cells can spontaneously form optic cups and retina

Human-derived stem cells can spontaneously form the tissue that develops into the part of the eye that allows us to see, according to a study published by Cell Press in the 5th anniversary issue of the journal Cell Stem Cell.

14 Jun 2012

Fluidigm unveils details of new C1 Single-Cell AutoPrep System at ISSCR meeting

Fluidigm today unveiled the details of its new C1 Single-Cell AutoPrep System to attendees at the International Society for Stem Cell Research (ISSCR) meeting in Yokohama, Japan.

13 Jun 2012

New combination therapy can help improve cure rates for neuroblastoma

An experimental treatment that combines intense chemotherapy with a radioactive isotope linked to synthesized neurotransmitter is being tested in newly diagnosed cases of high-risk neuroblastoma - a deadly, hard-to-cure childhood cancer.

13 Jun 2012

New tool should serve as cellular equivalent for children with CDG syndromes

Just as Gotham City uses the Bat Signal to call for Batman's aid, a new tool developed by scientists from the Sanford-Burnham Medical Research Institute in La Jolla, California, should serve as the cellular equivalent for children with glycosylation disorders, sometimes called "CDG syndromes."

13 Jun 2012

Ischemic stroke on the rise among N.J. children

Stroke is one of the top 10 causes of death among children according to the National Stroke Association. A new study published today shows that in New Jersey, the diagnosis of ischemic stroke in children, resulting from a loss or obstruction of blood to the brain, is on the rise.

13 Jun 2012

Researchers identify two proteins that are required to maintain kidney stem cells

Studying mice and humans, researchers at Washington University School of Medicine in St. Louis and their collaborators in Paris have identified two proteins that are required to maintain a supply of stem cells in the developing kidney.

12 Jun 2012

Study documents altruistic behavior by human embryonic stem cells

When most groups of mammalian cells are faced with a shortage of nutrients or oxygen, the phrase "every man for himself" is more apt than "all for one, one for all." Unlike colonies of bacteria, which often cooperate to thrive as a group, mammalian cells have never been observed to help one another out. But a new study led by a researcher at the Stanford University School of Medicine has shown that certain human embryonic stem cells, in times of stress, produce molecules that not only benefit themselves, but also help nearby cells survive.

12 Jun 2012

Higher quality bone from stem cells

UCLA stem cell scientists purified a subset of stem cells found in fat tissue and made from them bone that was formed faster and was of higher quality than bone grown using traditional methods, a finding that may one day eliminate the need for painful bone grafts that use material taken from the patient during invasive procedures.

11 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012

Second-hand cigarette smoke linked with moderate to severe urinary disorders in children

According to the Environmental Protection Agency, parents are responsible for 90 percent of children's exposure to environmental (second-hand) tobacco smoke. Children with mothers who smoke are at even higher-risk for developing health disorders.

8 Jun 2012

Scientists uncover origin of Langerhans cells

Scientists at A*STAR's Singapore Immunology Network (SIgN) uncovered the origin of a group of skin-deep immune cells that act as the first line of defence against harmful germs and skin infections. SIgN scientists discovered that these sentry cells of the skin, called the Langerhans cells (LCs), originate from two distinct embryonic sites - the early yolk sac and the foetal liver.

8 Jun 2012

ReproCELL to begin commercialization of human iPS-derived neurons for Alzheimer's

ReproCELL, Inc. announces today that the company will start commercializing human iPS-derived neurons in which an Alzheimer's disease related gene has been incorporated.

8 Jun 2012

Initial HSCT results from phase III trial on systemic sclerosis

Initial results from an international, investigator-initiated, open label phase III trial were presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism. Data indicate that haematopoietic stem cell transplantation (HSCT) results in better long term survival than conventional treatment for patients with poor prognosis early diffuse cutaneous systemic sclerosis.

7 Jun 2012